Table 1. Characteristics of the discovery and validation cohorts.
| Characteristics | Discovery cohort | Validation cohort |
|---|---|---|
| Number of patients | 212 | 38 |
| Gender (%) | ||
| Male | 90 (42.5) | 18 (47.4) |
| Female | 122 (57.5) | 20 (52.6) |
| Age at diagnosis, years, median [LQ–HQ] | 67 [59, 72] | 66 [57, 74] |
| Smoking status (%) | ||
| Current smoker | 39 (18.4) | 26 (68.4) |
| Former | 133 (62.7) | 6 (15.8) |
| Never | 29 (13.7) | 5 (13.2) |
| NA | 11 (5.2) | 1 (2.6) |
| Morphological subgroup (%) | ||
| Lepidic predominant | 13 (6.1) | 2 (5.3) |
| Papillary predominant | 27 (12.7) | 9 (23.7) |
| Acinar predominant | 82 (38.7) | 11 (28.9) |
| Micropapillary predominant | 26 (12.3) | 5 (13.2) |
| Solid predominant | 64 (30.2) | 11 (28.9) |
| Follow-up, months, median [LQ–HQ] | 13.2 [3, 30] | 18 [15, 29] |
| Vital status (%) | ||
| Alive | 151 (71.2) | 29 (76.3) |
| Deceased | 61 (28.8) | 9 (23.7) |
| Stage* (%) | ||
| I | 3 (1.4) | 0 (0) |
| IA | 51 (24.0) | 6 (15.8) |
| IB | 62 (29.2) | 14 (36.8) |
| IIA | 15 (7.1) | 1 (2.6) |
| IIB | 28 (13.2) | 4 (10.5) |
| IIIA | 33 (15.6) | 5 (13.2) |
| IIIB | 8 (3.8) | 8 (21.1) |
| IV | 12 (5.7) | 0 (0) |
Discovery cohort is from The Cancer Genome Atlas (TCGA) – lung ADC (LUAD) dataset. Validation cohort is generated by the Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). *, American Joint Committee on Cancer (AJCC) pathologic stage for the discovery cohort and the Union for International Cancer Control (UICC) stage for the validation cohort. LQ, low quartile; HQ, high quartile.